作者: Cyrus Cooper , Jean-Yves Reginster , Roland Chapurlat , Claus Christiansen , Harry Genant
DOI: 10.1185/03007995.2011.648758
关键词:
摘要: AbstractObjective:The osteoporosis drug strontium ranelate dissociates bone remodelling processes. It also inhibits subchondral resorption and stimulates cartilage matrix formation in vitro. Exploratory studies the trials report that reduces biomarkers of degradation, attenuates progression clinical symptoms spinal osteoarthritis, suggesting symptom- structure-modifying activity osteoarthritis. We describe rationale design a randomised trial evaluating efficacy safety knee osteoarthritis.Research design, methods, results:This double-blind, placebo-controlled (98 centres, 18 countries) includes ambulatory Caucasian men women aged ≥50 years with primary osteoarthritis medial tibiofemoral compartment (Kellgren Lawrence grade 2 or 3), joint space width (JSW) 2.5 to 5 mm, pain on most days previous month (intensity ≥40 mm visual analogue scale). ...